Fatal drug-induced immune hemolytic anemia due to cefotetan; A case study. 2008

Jim Perkins
Director, ENH Blood Banks, Evanston, IL, USA.

A case is described here of drug-induced immune hemolytic anemia (DIIHA) due to cefotetan administered to a post-partum woman who received the drug for infection prophylaxis at the time of caesarean section. Renewed fatal hemolysis occurred when the drug was given a second time 12 days after the first dose. The initial immunohematologic findings included a positive direct antiglobulin test (DAT) due to IgG and complement coating of the patient's RBCs as well as an eluate that did not react with RBCs in the absence of drug. The antibody was drug-dependent, reacting with both drug-coated RBCs as well as when the drug was added to a mixture of her serum and donor RBCs. Cefotetan has been a common cause of this uncommon problem. The clinical features of cefotetan DIIHA, classification of drug-induced antibodies, and the differential diagnosis of a positive DAT are briefly discussed.

UI MeSH Term Description Entries

Related Publications

Jim Perkins
January 1992, Transfusion,
Jim Perkins
November 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Jim Perkins
January 2022, International journal of clinical pharmacology and therapeutics,
Jim Perkins
February 1992, The Annals of pharmacotherapy,
Jim Perkins
December 2019, Journal of pharmacy practice,
Copied contents to your clipboard!